Raily Aesthetic Medicine International Holdings Limited Fundamental Analysis
Raily Aesthetic Medicine International Holdings Limited Fundamental Analysis
Raily Aesthetic Medicine International Holdings Limited (2135.HK) shows weak financial fundamentals with a PE ratio of 29.90, profit margin of 0.91%, and ROE of 1.67%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 26.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2135.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2135.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate2135.HK shows balanced valuation metrics.
Growth Score
Weak2135.HK faces weak or negative growth trends.
Financial Health Score
Moderate2135.HK shows balanced financial health with some risks.
Profitability Score
Moderate2135.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 2135.HK Expensive or Cheap?
P/E Ratio
2135.HK trades at 29.90 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 2135.HK's PEG of 0.41 indicates potential undervaluation.
Price to Book
The market values Raily Aesthetic Medicine International Holdings Limited at 0.48 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.22 times EBITDA. This is generally considered low.
How Well Does 2135.HK Make Money?
Net Profit Margin
For every $100 in sales, Raily Aesthetic Medicine International Holdings Limited keeps $0.91 as profit after all expenses.
Operating Margin
Core operations generate 2.62 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.67 in profit for every $100 of shareholder equity.
ROA
Raily Aesthetic Medicine International Holdings Limited generates $0.72 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Raily Aesthetic Medicine International Holdings Limited produces operating cash flow of $35.47M, showing steady but balanced cash generation.
Free Cash Flow
Raily Aesthetic Medicine International Holdings Limited generates strong free cash flow of $32.73M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.06 in free cash annually.
FCF Yield
2135.HK converts 63.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.90
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.41
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.48
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.28
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.55
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.77
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.007
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How 2135.HK Stacks Against Its Sector Peers
| Metric | 2135.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.90 | 29.63 | Neutral |
| ROE | 1.67% | 223.00% | Weak |
| Net Margin | 0.91% | -38669.00% (disorted) | Weak |
| Debt/Equity | 0.55 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 0.77 | 4.30 | Weak Liquidity |
| ROA | 0.72% | -379.00% (disorted) | Weak |
2135.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Raily Aesthetic Medicine International Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation